DLL3 Battlefield Upgrade: From BiTE to ADC, Heng Rui, Xin Da, and Zai Ding Take Turns to Showcase
Click the blue text Follow us This Issue Highlights In recent years, the field of tumor immunotherapy has welcomed an important new target—DLL3. As a ligand of the Notch signaling pathway, DLL3 (Delta-like ligand 3) plays a key role in the progression of various malignant tumors, particularly in small cell lung cancer (SCLC) and neuroendocrine … Read more